Sugi Predict

Sugi Predict / Compounds / SCHEMBL7428953

SCHEMBL7428953

SCHEMBL7428953

NC(=O)C1CCN(O)CC1

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.56
▸ GAA P10253 3/20 0.48
▸ ALDH1A1 P00352 3/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ APEX1 P27695 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ PKM P14618 1/20 0.41
▸ CHRM1 P11229 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19642625 0.85 — —
SCHEMBL8158343 0.82 SMN1; SMN2 (0.54) SMN1; SMN2GAAALDH1A1TDP1CYP3A4
SCHEMBL5074242 0.79 SMN1; SMN2 (0.56) SMN1; SMN2GAAALDH1A1TDP1CYP3A4
SCHEMBL509608 0.77 SMN1; SMN2 (0.54) SMN1; SMN2GAAALDH1A1TDP1CYP3A4
SCHEMBL7358278 0.77 GAA (0.57) SMN1; SMN2GAAALDH1A1TDP1KDM4E
SCHEMBL11039671 0.77 SMN1; SMN2 (0.59) SMN1; SMN2GAAALDH1A1TDP1CYP3A4
SCHEMBL13116870 0.77 SMN1; SMN2 (0.54) SMN1; SMN2GAAALDH1A1TDP1CYP3A4
SCHEMBL274448 0.77 SMN1; SMN2 (0.59) SMN1; SMN2GAAALDH1A1TDP1CYP3A4
SCHEMBL14421937 0.77 SMN1; SMN2 (0.54) SMN1; SMN2GAAALDH1A1TDP1CYP3A4
SCHEMBL9797557 0.76 SMN1; SMN2 (0.50) SMN1; SMN2GAAALDH1A1TDP1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109305941-A Bis- target spot inhibitor of a kind of HDACs and MDM2 and its preparation method and application 中国人民解放军第二军医大学 2019-02-05 — — CN claimed
EP-1263755-A2 CYCLIC BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA Bristol-Myers Squibb Pharma Company (US) 2002-12-11 — — EP claimed
WO-2001070673-A2 CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-09-27 — — WO claimed
US-20210338653-A1 N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES NEUROCRINE BIOSCIENCES, INC. 2021-11-04 — — US disclosed
US-11033539-B2 Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases NEUROCRINE BIOSCIENCES, INC. (US) 2021-06-15 — — US disclosed
CN-109563043-A SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 葛兰素史密斯克莱知识产权发展有限公司 2019-04-02 — — CN disclosed
CN-109305941-A Bis- target spot inhibitor of a kind of HDACs and MDM2 and its preparation method and application 中国人民解放军第二军医大学 2019-02-05 — — CN disclosed
US-20180325887-A1 N-[2-(1-BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES NEUROCRINE BIOSCIENCES, INC. 2018-11-15 — — US disclosed
WO-2018021977-A1 GLYCINE METABOLISM MODULATORS AND USES THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2018-02-01 — — WO disclosed
EP-3110427-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE Urigen Pharmaceuticals, Inc. (US) 2017-01-04 — — EP disclosed
WO-2015127416-A1 COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE URIGEN PHARMACEUTICALS, INC. (US) 2015-08-27 — — WO disclosed
CN-1481377-A Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteinases and TNF-alpha ����˹�ж�-����˹˹����ҩƷ��˾ 2004-03-10 — — CN disclosed
CN-1387514-A Aromatic sulfone hydroxamic acid metalloprotease inhibitor SEARLE & CO (US) 2002-12-25 — — CN disclosed
CN-1370144-A Aromatic sulfone hydroxamic acid metalloprotease inhibitor SEARLE & CO (US) 2002-09-18 — — CN disclosed
CN-1279669-A Aromatic sulfone hydroxamic acid metalloprotease inhibitors SEARLE & CO (US) 2001-01-10 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11033539-B2 Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic receptor 4(M4) antagonists for treating neurological diseases CHRM2, CHRM4, CHRM1 SMN1; SMN2 511/4885GAA 1102/4885ALDH1A1 4256/4885
US-20180325887-A1 N-[2-(1-BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES CHRM1, CHRM2, CHRM4 SMN1; SMN2 245/4885GAA 1918/4885ALDH1A1 4504/4885
US-20210338653-A1 N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES CHRM2, CHRM1, CHRM4 SMN1; SMN2 344/4885GAA 1965/4885ALDH1A1 4529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.